<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954939</url>
  </required_header>
  <id_info>
    <org_study_id>UW12-389</org_study_id>
    <nct_id>NCT02954939</nct_id>
  </id_info>
  <brief_title>The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis</brief_title>
  <official_title>The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets and Relationship With Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the effect of mycophenolate mofetil and cyclosphosphamide on
      lymphocyte subsets in patients with proliferative lupus nephritis. Patients with
      biopsy-proven Class III/IV+/-V LN were randomized to received: 1) prednisolone (0.8mg/kg/day)
      plus CTX (1.5-2mg/kg/d) for 6 months) followed by Azathioprine (AZA) (1-1.5mg/kg/d)
      maintenance; OR 2) prednisolone (0.8mg/kg/d) plus MMF (1g bd) for 6 months, followed by MMF
      (tapered according to clinical status) as maintenance. The lymphocyte subsets and serum
      cytokine profiles will be measured at 4-, 12-, and 24-, 36- and 48 weeks after induction
      treatment. The lymphocyte subsets and serum cytokine profiles will be compared between the
      two treatment regimens, and also correlated with subsequent risk of relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigated the effect of mycophenolate mofetil and cyclosphosphamide on
      lymphocyte subsets in patients with proliferative lupus nephritis. Patients with
      biopsy-proven Class III/IV+/-V LN were randomized to received: 1) prednisolone (0.8mg/kg/day)
      plus CTX (1.5-2mg/kg/d) for 6 months) followed by Azathioprine (AZA) (1-1.5mg/kg/d)
      maintenance; OR 2) prednisolone (0.8mg/kg/d) plus MMF (1g bd) for 6 months, followed by MMF
      (tapered according to clinical status) as maintenance. The lymphocyte subsets and serum
      cytokine profiles will be measured at 4-, 12-, and 24-, 36- and 48 weeks after induction
      treatment. The lymphocyte subsets and serum cytokine profiles will be compared between the
      two treatment regimens, and also correlated with subsequent risk of relapse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphocyte subset profile (CD8+ T cells, CD4+ Th1, Th2, Th17 &amp; Treg), Na√Øve &amp; memory B cells, plasma cells</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum cytokine profile (IL-2, IL-5, IL-6, IL-7, IL-10, IL-17, IL-21, IL-23, IFN-alpha, IFN-gamma, TGF-beta)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>MMF-MMF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTX-AZA</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF-MMF</intervention_name>
    <description>Class III/IV+/-V lupus nephritis patients to receive PRED+MMF</description>
    <arm_group_label>MMF-MMF</arm_group_label>
    <other_name>PRED; MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX-AZA</intervention_name>
    <description>Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA</description>
    <arm_group_label>CTX-AZA</arm_group_label>
    <other_name>PRED; CTX; AZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1. Patients with biopsy proven Class III/IV+/-V LN (ISN/RPS classification) and active
        nephritis as indicated by an increase of proteinuria &gt;1g/day and/or rise in serum
        creatinine by &gt;15% compared with baseline, with or without serological reactivation.

        2. Willing to give informed consent

        Exclusion Criteria:

          1. Patients who have received calcineurin inhibitors or proliferation signal inhibitors
             as maintenance immunosuppression in the preceding 3 months

          2. Patients have received biologics therapy (e.g. rituximab, abatacept) in the preceding
             12 months

          3. Patients who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Desmond YAP, MD (HK)</last_name>
    <phone>22554385</phone>
    <email>desmondy@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desmond Yap, MD (HK)</last_name>
      <phone>85222554385</phone>
      <email>desmondy@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lupus nephritis</keyword>
  <keyword>lymphocyte subsets</keyword>
  <keyword>cytokines</keyword>
  <keyword>mycophenolate mofetil</keyword>
  <keyword>cyclophosphamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

